(News Bulletin 247) – Pfizer Inc. today announced positive topline results from the Phase 3 TALAPRO-2 study of Talzenna (talazoparib).

- Advertisement -

The study met its primary endpoint with a significant improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI in the treatment of metastatic prostate cancer, non-metastatic prostate cancer and prostate cancer castration-sensitive metastatic disease (CPMSC)

The results showed a trend towards improvement in overall survival, a key secondary endpoint, at the time of analysis, but these data are not yet mature.

- Advertisement -

Other secondary endpoints are being analyzed.

“These data underscore the potential of Talzenna in combination with XTANDI to become a new standard of care for mCPCR,” said Chris Boshoff, MD, Ph.D., development manager, oncology, global product development, Pfizer.

“We believe that Talzenna in prostate cancer could become the next potential blockbuster opportunity in our leading Pfizer Oncology portfolio,” adds Suneet Varma, Global President of Oncology and US, Pfizer.

Copyright (c) 2022 News Bulletin 247. All rights reserved.